本文選題：前列腺癌 + 代謝組學(xué)��； 參考：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2017年11期

【摘要】：前列腺癌(PCA)是全球第二個最常見的男性癌癥,同時也是男性癌癥死亡的第五大原因。早期發(fā)現(xiàn)和危險度分級是提高前列腺癌患者生存率最有效的方法。目前前列腺癌的生物標(biāo)志物缺乏足夠的敏感性和特異性,而代謝產(chǎn)物作為生物標(biāo)志物可以作為一種新的提高早期診斷的工具。我們檢索了154篇出版物,其中27篇和38篇是分別關(guān)于尿液和血清代謝組學(xué)分析的原研論文,提示了核磁共振波譜分析是一種很有前景的檢測方法,可用于測量復(fù)雜的樣本中代謝物的濃度,具有良好的重現(xiàn)性、高靈敏度和樣本處理的便捷性。特別是基于核磁共振的代謝組學(xué)檢測尿液已成為檢測前列腺癌的早期潛在的危險度分級和監(jiān)測治療效果的有效的方法。
[Abstract]:Prostate cancer (PCA) is the second most common cancer in men and the fifth leading cause of cancer deaths in men. Early detection and risk grading are the most effective methods to improve the survival rate of prostate cancer patients. At present, the biomarkers of prostate cancer lack sufficient sensitivity and specificity, and metabolites as biomarkers can be used as a new tool to improve early diagnosis. We searched 154 publications, of which 27 and 38 were original papers on urine and serum metabonomics analysis, respectively, suggesting that nuclear magnetic resonance spectroscopy is a promising method for detection. It can be used to measure the concentration of metabolites in complex samples. It has good reproducibility, high sensitivity and convenient sample processing. In particular, metabonomics based on MRI has become an effective method for early detection of prostate cancer potential risk classification and monitoring of therapeutic efficacy.
【作者單位】： Department
【基金】：Project supported by the Joint Research Project(No.PW2016D-13)of Pudong New Area Health and Family Planning Committee,Shanghai,China
【分類號】：R445.2;R737.25

【相似文獻(xiàn)】

相關(guān)博士學(xué)位論文 前1條

1 范校周;基于納米泡的前列腺癌超聲靶向診斷及治療的實驗研究[D];第三軍醫(yī)大學(xué);2017年

相關(guān)碩士學(xué)位論文 前1條

1 岳園園;靶向前列腺癌的兩種探針的研究[D];鄭州大學(xué);2017年

，

本文編號：1784972